VALUE HEALTH REPLACING LOW-DOSE MEVACOR WITH LESCOL: SANDOZ PRODUCT IS ONE OF NEW BREED OF "MANAGED CARE" PRODUCTS, EXPRESS SCRIPTS PRESIDENT TELLS ANALYSTS
Executive Summary
The Value Health formularies will add the Sandoz HMG-CoA reductase inhibitor Lescol in place of the Merck pioneer in the class, Mevacor, to take advantage of Sandoz discount prices, Value Health Chairman Robert Patricelli reported May 10 at Alex. Brown's 19th Annual Health Care Seminar in Baltimore.